These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7285527)

  • 1. [Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
    Piccinin GL; Piccirilli M; Agostini L
    Clin Ter; 1981 Mar; 96(6):621-6. PubMed ID: 7285527
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
    Piccirilli M; Piccinin GL; La Medica A
    Clin Ter; 1981 Feb; 96(3):335-40. PubMed ID: 7307449
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 11. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 12. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effect of the temporary interruption of treatment of long-term parkinsonian patients: role of the peripheral metabolism of L-DOPA].
    García García B; Hernández Calzadilla C; Barajas García-Talavera F; Fernández Martín F; Pérez de Paz A; Rodríguez Díaz M
    Arch Neurobiol (Madr); 1986; 49(3):145-52. PubMed ID: 3741052
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 15. L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Adv Neurol; 1990; 53():431-5. PubMed ID: 2122649
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

  • 17. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 19. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
    Diamond SG; Markham CH
    Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633
    [No Abstract]   [Full Text] [Related]  

  • 20. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.